How to use this document:

First Page		Document Content
Date: 2014-12-11 13:07:15 Gilead Sciences Fixed dose combination Organofluorides Cyclopropanes Antiretroviral drug Efavirenz Reverse-transcriptase inhibitor Emtricitabine Abacavir Chemistry Organic chemistry Non-nucleoside reverse transcriptase inhibitors		How to use this document: Add to Reading List Source URL: www.vdh.state.va.us Download Document from Source Website File Size: 148,53 KB Share Document on Facebook

	January 22, 2016 BUSY WEEK? Here are the TOP INDUSTRY NEWS stories you might have missed, as selected by DCAT Editorial Director Patricia Van Arnum. 1. Gilead Sciences, Galapagos Close $2 Billion Deal for AntiInfla DocID: 1rBxh - View Document
	Case 3:16-cvDocument 1 FiledPage 1 ofDorian S. Berger, CA State Bar NoDaniel P. Hipskind, CA State Bar No DocID: 1rqYi - View Document
	March 4, 2016 BUSY WEEK? Here are the TOP INDUSTRY NEWS stories you might have missed, as selected by DCAT Editorial Director Patricia Van Arnum. Sponsored By: DocID: 1rdax - View Document
	Microsoft Word - GILEAD BRIEFING DocID: 1r2Vm - View Document
	Patient Name:________________________________________ Date of Birth:__________________ Truvada® for Pre-Exposure Prophylaxis (PrEP) Medication Assistance Program Page 1 of 4 DocID: 1qMRc - View Document